WHITE PAPER:
PGx is Evolving; Shouldn’t Your Content Coverage?
Closing the diversity gap in pharmacogenomics (PGx) research
Adverse reactions to medicines are estimated to be the 4th leading cause of death globally, because currently available drugs do not work the same way for everyone. PGx insights are plagued by a lack of diversity.
The design of VeriDose® Core v2.0 has evolved to change the paradigm.
By incorporating 85 variants across 16 genes, including actionable AMP Tier 1 and Tier 2 alleles, this is the most comprehensive targeted panel for pan-ethnic PGx analysis. Learn how your lab can lead the field by shaping the future of healthcare information with every run.
In this white paper, discover:
- How VeriDose® Core v2.0 aligns with AMP, CPIC, and FDA recommendations
- How to scale PGx analysis with the MassARRAY® System workflow
- The importance of HLA detection and how it accelerates precision medicine research
- How the panel was designed, tested, and validated
Built for scale. Backed by science. Designed for equity.
Ready to upgrade your lab’s research capabilities?
The future of PGx research is in your hands. Download the white paper now and learn how VeriDose® Core v2.0 can drive the next evolution in PGx research.
Download Now
Complete the form to receive the exclusive white paper.